Literature DB >> 10620061

Coordinated maturational regulation of PHEX and renal phosphate transport inhibitory activity: evidence for the pathophysiological role of PHEX in X-linked hypophosphatemia.

T Nesbitt1, I Fujiwara, R Thomas, Z S Xiao, L D Quarles, M K Drezner.   

Abstract

The mechanism by which inactivating mutations of PHEX (phosphate-regulating gene with homologies to endopeptidases on the X chromosome) cause X-linked hypophosphatemia remains unknown. However, recent reports suggest errant PHEX activity in osteoblasts may fail to inactivate a phosphaturic factor produced by these cells. To test this possibility, we examined coordinated maturational expression of PHEX and production of phosphate transport inhibitory activity in osteoblasts from normal and hyp-mice. We assessed the inhibitory activity in conditioned medium by examining the effects on opossum kidney cell phosphate transport and osteoblast PHEX expression by reverse transcriptase-polymerase chain reaction during a 17-day maturational period. Inhibitory activity increased as a function of osteoblast maturational stage, with no activity after 3 days and persistent activity by 6 days of culture. More significantly, equal phosphate transport inhibitory activity in conditioned medium from normal and hyp-mouse osteoblasts (control 1.90 +/- 0.12, normal 1.48 +/- 0.10, hyp 1.45 +/- 0.04 nmol/mg of protein/minute) was observed at 6 days. However, by 10 days hyp-mouse osteoblasts exhibited greater inhibitory activity than controls, and by 17 days the difference in phosphate transport inhibition maximized (control 2.08 +/- 0.09, normal 1.88 +/- 0.06, hyp 1.58 +/- 0.06 nmol/mg of protein/minute). Concurrently, we observed absent PHEX expression in normal osteoblasts after 3 days, limited production at 6 days, and significant production by day 10 of culture, while hyp-mouse osteoblasts exhibited limited PHEX activity secondary to an inactivating mutation. The data suggest that the presence of inactivating PHEX mutations results in the enhanced renal phosphate transport inhibitory activity exhibited by hyp-mouse osteoblasts.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10620061     DOI: 10.1359/jbmr.1999.14.12.2027

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  16 in total

1.  Characterization of PHEX endopeptidase catalytic activity: identification of parathyroid-hormone-related peptide107-139 as a substrate and osteocalcin, PPi and phosphate as inhibitors.

Authors:  G Boileau; H S Tenenhouse; L Desgroseillers; P Crine
Journal:  Biochem J       Date:  2001-05-01       Impact factor: 3.857

2.  Evidence for a bone-kidney axis regulating phosphate homeostasis.

Authors:  L Darryl Quarles
Journal:  J Clin Invest       Date:  2003-09       Impact factor: 14.808

Review 3.  Review of the dental implications of X-linked hypophosphataemic rickets (XLHR).

Authors:  Martin M I Sabandal; Peter Robotta; Sebastian Bürklein; Edgar Schäfer
Journal:  Clin Oral Investig       Date:  2015-02-13       Impact factor: 3.573

4.  Serum MEPE-ASARM-peptides are elevated in X-linked rickets (HYP): implications for phosphaturia and rickets.

Authors:  Doron Bresler; Jan Bruder; Klaus Mohnike; William D Fraser; Peter S N Rowe
Journal:  J Endocrinol       Date:  2004-12       Impact factor: 4.286

5.  Human recombinant endopeptidase PHEX has a strict S1' specificity for acidic residues and cleaves peptides derived from fibroblast growth factor-23 and matrix extracellular phosphoglycoprotein.

Authors:  Marcelo Campos; Constance Couture; Izaura Y Hirata; Maria A Juliano; Thomas P Loisel; Philippe Crine; Luiz Juliano; Guy Boileau; Adriana K Carmona
Journal:  Biochem J       Date:  2003-07-01       Impact factor: 3.857

6.  Surface plasmon resonance (SPR) confirms that MEPE binds to PHEX via the MEPE-ASARM motif: a model for impaired mineralization in X-linked rickets (HYP).

Authors:  Peter S N Rowe; Ian R Garrett; Patricia M Schwarz; David L Carnes; Eileen M Lafer; Gregory R Mundy; Gloria E Gutierrez
Journal:  Bone       Date:  2004-11-24       Impact factor: 4.398

7.  Role of matrix extracellular phosphoglycoprotein in the pathogenesis of X-linked hypophosphatemia.

Authors:  Shiguang Liu; Thomas A Brown; Jianping Zhou; Zhou-Sheng Xiao; Hani Awad; Farshid Guilak; L Darryl Quarles
Journal:  J Am Soc Nephrol       Date:  2005-04-20       Impact factor: 10.121

8.  Degradation of MEPE, DMP1, and release of SIBLING ASARM-peptides (minhibins): ASARM-peptide(s) are directly responsible for defective mineralization in HYP.

Authors:  Aline Martin; Valentin David; Jennifer S Laurence; Patricia M Schwarz; Eileen M Lafer; Anne-Marie Hedge; Peter S N Rowe
Journal:  Endocrinology       Date:  2007-12-27       Impact factor: 4.736

Review 9.  The wrickkened pathways of FGF23, MEPE and PHEX.

Authors:  Peter S N Rowe
Journal:  Crit Rev Oral Biol Med       Date:  2004-09-01

10.  The use of pre-operative imaging and intraoperative parathyroid hormone level to guide surgical management of tertiary hyperparathyroidism from X-linked hypophosphatemic rickets: a case report.

Authors:  Matthew D Neal; Berthony Deslouches; Jennifer Ogilvie
Journal:  Cases J       Date:  2009-09-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.